Previous Article | Next Article ![]()
Journal of Bacteriology, March 2004, p. 1415-1422, Vol. 186, No. 5
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.5.1415-1422.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Bereich Mikrobiologie, Department Biologie I, Ludwig-Maximilians-Universität München, D-80638 Munich, Germany,1 Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6018,2 Department of Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada3
Received 24 July 2003/ Accepted 13 November 2003
|
|
|---|
|
|
|---|
Compared to other T4SS, the T-DNA translocation system from A. tumefaciens has been studied in the greatest detail (3, 11). Its 12 components (VirB1 to VirB11 and VirD4) localize to the inner and the outer membrane, and different lines of evidence suggest that this complex spans the periplasm. Biochemical experiments suggested that VirB7, VirB8, VirB9, and VirB10, which are mostly exposed to the periplasm but anchored to the membranes, constitute the core complex required for the stabilization of many other membrane-bound VirB proteins (1, 4, 7, 14, 18, 19, 29). Protein-protein interactions between VirB7 to VirB10 were also detected with the yeast two-hybrid system (13, 14). VirB8 and VirB10 contain N-terminal hydrophobic domains and are likely anchored to the inner membrane. In contrast, the lipoprotein VirB7 predominantly localizes to the outer membrane together with covalently linked VirB9. The T4SS core likely links the surface-exposed T-pilus components VirB2 and VirB5 to the cell, and VirB6 and VirB7 play a key role during that process (17, 25, 27, 29, 32, 45). The mechanism of T4SS assembly is unknown, and energy provided by one or more of the nucleotide triphosphatases VirB4, VirB11, and VirD4 is believed to energize this process (30, 43).
The murein layer imposes a barrier to the assembly of trans-envelope structures, and VirB1 likely exerts its effect here (5, 15, 16, 28). VirB1 is required for efficient T4SS function, but virB1 deletion strains of A. tumefaciens were reported to retain between 1 and 10% residual virulence (8, 39). Similarly, in the absence of VirB1 ortholog P19, plasmid R1 conjugation and R17 phage infection were reduced to 10% of the wild-type level and traL mutants of pKM101 had 5% residual activity (5, 54). The finding that VirB1 is not essential was attributed to its putative function as a lytic transglycosylase, which may facilitate T4SS assembly by localized lysis of the peptidoglycan (39). The relatively thin murein layer of gram-negative bacteria may permit a reduced level of T4SS assembly even in the absence of VirB1 orthologs (28). Alternatively, cellular enzymes may partly substitute for its function (26). Direct evidence for the transglycosylase activity has not been presented, but VirB1 derivatives with alterations in the putative active sites had strongly reduced virulence (39). Overproduction of the VirB1 ortholog P19 from plasmid R1 led to cell lysis, implying a role in murein metabolism (6). In addition to its suggested function as a transglycosylase, there may be an additional contribution of VirB1 to T4SS functionality. VirB1 undergoes C-terminal processing after export into the periplasm, resulting in an N-terminal transglycosylase domain and the 14-kDa C-terminal processing product VirB1*, which is partly secreted across the outer membrane (2). Both domains partly complemented a virB1 deletion mutant, implying that they independently contribute to virulence (37). Cross-linking experiments showed that VirB1* localizes in close proximity to VirB9, and this interaction may be required for T4SS function (2). A role of VirB1 in T4SS assembly via interactions with other proteins was further supported by the results of two-hybrid experiments and by its impact on the localization of VirB10 in the cell (35, 53).
We present here a detailed analysis of the consequences of a mutational alteration of the active site of VirB1, showing that it contributes to efficient gene transfer from A. tumefaciens but it is not required for processing of VirB1 and secretion of the C-terminal VirB1* product. In addition, our data strongly suggest that the protein contributes a transglycosylase-independent function to the type IV secretion process. Functional complementation with VirB1 orthologs from some other T4SS was achieved, suggesting that the requirement for transglycosylase activity is conserved among T4SS.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids
|
Brucella suis virB1 was amplified from pUCvirB (oligonucleotides BsB1-5', 5'-GGACCATGGTGCCATTCCTTGTCCTCGCGC-3', and BsB1-3', 5'-GCTAGTACTTAGAAAACAACTACGCCGTCCGTATTATCCTTC-3'). TraL was amplified from pKM101 (oligonucleotides TraL5, 5'-GGGGCCATGGGTAAACATCCAAAACTCC-3', and TraL3', 5'-GAAAGTACTCATTCCCCCTTCG-3') (41). Open reading frame (ORF) 169 was amplified from the F plasmid (oligonucleotides 169-N1, 5'-GGGGCCATGGCAAAATGGATGTTAGCCATCTGCCT-3', and 169-C, 5'-CCCAGTACTTAATTGTTCTGCACGCTGTTAATTTC-3') (22). The reading frame of HP0523 was amplified from Helicobacter pylori 26695 chromosomal DNA (oligonucleotides Cag4-5, 5'-GGGGCCATGGTCGAGAAATGGATTGGTCT-3', and Cag4-3, 5'-CCCAGTACTACTCGTTATATCGCACTTG-3') (49). The fragments were cleaved with NcoI and ScaI (underlined in oligonucleotide sequences above) followed by ligation to similarly cut pTrc200 and sequencing with an ABI 310 sequencer, resulting in pTrcB1s, pTrcTraL, pTrc169, and pTrc523.
The codons determining active-site Glu residues were changed to Ala in pTrcB1 (Glu60), pTrcB1s (Glu27), and pTrcTraL (Glu53) by site-directed mutagenesis by using the Gene editor in vitro site-directed mutagenesis system (Promega) according to the supplier's description. The genes encoding VirB1 and its orthologs were subcloned and subjected to mutagenesis as follows. The virB1 gene from pTrcB1 was excised with Eco32I/HindIII and ligated into similarly cut pBAD18 followed by mutagenesis with oligonucleotide B1M5 (GCAGCGATCGCTCAGGTCGCTAGCCGCTTTGATCCGCTTGCT). The virB1 gene from pTrcB1s was excised with NcoI/HindIII and ligated into similarly cut pT7-7 followed by mutagenesis with oligonucleotide B1suisM5 (GCAGCAATCGTGCAGGTCGCTAGCGGCTTCAATCCTTATGCA). The traL gene from pTrcTraL was excised with NcoI/HindIII and ligated into similarly cut pT7-7 followed by mutagenesis with oligonucleotide TraLM5 (GCGTACATCGTCGGCCATGCTAGCTCAAATGGACCGTACAGG). Mutations were identified by restriction analysis with NheI (underlined above) and confirmed by sequencing.
Cultivation of A. tumefaciens and analysis of exocellular fractions. Overnight cultures of A. tumefaciens were grown in YEB medium (0.5% beef extract, 0.5% peptone, 0.1% yeast extract, 0.5% sucrose, 2 mM MgSO4) in the absence of antibiotics (wild-type strains) or with SPC (300 µg/ml) and streptomycin (100 µg/ml) for the propagation of pTrc200 derivatives. For propagation of pLS1, CAR was added at 150 µg/ml, and for the selection of UIA143(pTiA6) pLS1 transconjugants, erythromycin (ERY) was added at 150 µg/ml in addition to CAR. Further, the cells were inoculated to an optical density at 600 nm of 0.1 in liquid AB medium (10 g of glucose/liter, 4 g of MES [morpholineethanesulfonic acid]/liter, 0.3 g of MgSO4 · 7 H2O/liter, 0.15 g of KCl/liter, 0.01 g of CaCl2/liter, 0.0025 g of FeSO4 · 7H2O/liter, and 1 mM potassium phosphate [pH 5.5]) and grown for 5 h at 20°C followed by specific procedures depending on the assay used. First, for the analysis of VirB1* secretion in liquid cultures, cells were grown at 20°C for 18 h with 0.5 mM isopropyl-ß-D-thiogalactopyranoside (IPTG) for the induction of the trc promoter with or without 200 µM acetosyringone (AS) for virulence gene induction. VirB1* was precipitated from cell-free culture supernatants with acetone as described followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis (2). Second, for the isolation of surface-exposed T-pili, 1 ml of cells was plated per large (15 cm2) AB medium plate (20 g of agar/liter) with or without 200 µM AS and the plates were further incubated at 20°C for 4 days. T-pili were isolated from the cells grown on 4 plates each with and without AS by shearing and ultracentrifugation as described previously (45). Third, for plant infection experiments, leaf squares (4 by 4 mm) of Nicotiana tabacum cv. Havana 425 were cocultivated with the bacteria in the presence of 0.5 mM IPTG and 300 µM AS on hormone-free Murashige-Skoog medium for 2 days at 25°C, rinsed with Luria-Bertani plus 200 µg of vancomycin/ml and 200 µg of timentin/ml, and then cultivated on hormone-free Murashige-Skoog medium plus 200 µg of vancomycin/ml and 200 µg of timentin/ml at 25°C in the dark (35). Tumor formation was scored 12 days after the start of the cocultivation. Fourth, for the analysis of pLS1 donor activity, A348 and PC1001 carrying pTrc200 with and without VirB1 ortholog-encoding genes were cocultivated with UIA143(pTiA6) recipient cells in a 1:5 ratio for 3 days on AB minimal medium agar containing 500 µM AS and 500 µM IPTG followed by plating on selective agar media (CAR, 150 µg/ml; ERY, 150 µg/ml) and quantitation of recipient and donor cells as described previously (9). Fifth, for the analysis of pLS1 recipient activity, donor A348 pLS1 cells were cocultivated with PC1001 recipient cells carrying pTrc200 with and without VirB1 ortholog-encoding genes in a 5:1 ratio for 2 days on AB induction medium plus 500 µM AS and 500 µg of IPTG/ml followed by plating on Luria-Bertani agar plus antibiotics (150 µg of CAR/ml and/or 100 µg of SPC/ml) as necessary for quantitation of donors, recipients, and transconjugants as described previously (35).
SDS-PAGE and Western blotting. Cells and exocellular fractions were incubated in Laemmli sample buffer for 5 min at 100°C followed by SDS-PAGE according to the method of Laemmli (VirB1 and VirB8) (31) or Schägger and von Jagow (VirB2) (44), and Western blotting was performed in a tank blot apparatus. Detection was performed with a chemiluminescence-based system (NEN) with A. tumefaciens strain C58 VirB protein-specific antisera.
|
|
|---|
virB1) for analysis of their biological activities. In addition, the genes encoding VirB1, VirB1s, and TraL were modified by site-directed mutagenesis to change the essential active-site Glu residues of their respective products.
![]() View larger version (64K): [in a new window] |
FIG. 1. VirB1 orthologs and active-site mutants used in this study. (A) Schematic representation of the analyzed proteins and their amino acid sequence identities (percentages noted on the right) to A. tumefaciens C58 VirB1. Amino acid residues in boxes A, B, and C (black boxes) are implicated in the enzymatic activity of lytic transglycosylases. They were assigned in the different orthologs according to the method of Bayer et al. (5). Signal peptides (grey boxes) were assigned by the SignalP V1.1 algorithm (http://www.cbs.dtu.dk/services/SignalP). The C-terminal processing site of VirB1 (A173QQ) is shown as a hatched box. (B) Alignment of VirB1 orthologs investigated in this study; residues identical to those of VirB1 are shaded. Conserved residues are indicated by black boxes A, B, and C, and the putative active-site Glu residues are labeled with a star. Active-site residues corresponding to Glu60 from A. tumefaciens VirB1 were changed to Ala in VirB1s and TraL in the course of this study. The alignment was generated with the MegAlign program (DNA Star).
|
A (Fig. 2), demonstrating that the putative active site is not required for stability, processing, and secretion. Different assays were conducted to assess the complementation of the A. tumefaciens virB1 defect.
![]() View larger version (37K): [in a new window] |
FIG. 2. Processing of VirB1 and secretion of VirB1*. Strains A348 and PC1001 ( virB1) carrying pTrc200 (pTrc), pTrcB1 (VirB1), or pTrcB1E A (VirB1E A) were cultivated under virulence gene-inducing (+AS) or noninducing conditions (-AS). IPTG was added to cultures carrying pTrc200 constructs for induction of gene expression from the trc promoter. Cell lysates (A) and secreted proteins precipitated from the supernatant (B) were separated by SDS-PAGE followed by Western blotting with A. tumefaciens C58 VirB1-specific antiserum. Arrows indicate VirB1 and its C-terminal processing product VirB1*. A VirB1* processing product of strain A348 VirB1 was not detected with strain C58 VirB1-specific antiserum. Numbers on the right indicate reference proteins.
|
virB1) carrying pTrc200 with or without virB1 ortholog-carrying genes were grown on AB agar plates under virulence gene-inducing conditions followed by subcellular fractionation and analysis of VirB protein content. Analysis of cell lysates with VirB2- and VirB8-specific antisera showed that the accumulation of the major T-pilus component as well as of the T4SS core component VirB8 were not affected by the absence of VirB1 (Fig. 3A). Surface-exposed high-molecular-mass structures were removed from the cells by shearing and ultracentrifugation, and as previously described, significant amounts of VirB2 were not detected in exocellular fractions from strain PC1001 (Fig. 3B). The introduction of pTrcB1 and of pTrcB1s restored T-pilus formation almost to wild-type levels. In two of three experiments, pTrcTraL showed weak complementing activity, but pTrc169 and pTrc523 never restored T-pilus formation. Similarly, plasmids directing the production of active site variants of VirB1, VirB1s, and TraL did not reproducibly complement T-pilus formation, demonstrating that the putative active site is required. Since T-pilus formation it is not readily amenable to quantitation, low degrees of complementation are difficult to monitor and it does not permit conclusions on substrate translocation.
![]() View larger version (43K): [in a new window] |
FIG. 3. Complementation of T-pilus formation by strain PC1001. Strains A348 and PC1001 ( virB1) carrying pTrc200 and virB1 ortholog-encoding constructs were cultivated under virulence gene-inducing (+AS) or noninducing conditions (-AS). IPTG was added to cultures carrying pTrc200 constructs for induction of gene expression from the trc promoter. Cell lysates (A) and exocellular high-molecular-mass T-pilus fractions (B) were separated by SDS-PAGE followed by Western blotting with VirB2- or VirB8-specific antisera. The strains used are as follows: A348 and PC1001 carrying pTrc200 (pTrc), pTrcB1 (VirB1), pTrcB1s (VirB1s), pTraL (TraL), pTrcB1E A (VirB1E A), pTrcB1sE A (VirB1sE A), pTrcTraLE A (TraLE A), pTrc169 (F169), or pTrc523 (HP0523). The experiments were performed three times, and the arrows indicate detection of T-pilus component VirB2 in exocellular fractions in at least two of those experiments. Numbers on the right indicate reference proteins.
|
A, which directs the production of an active-site variant of VirB1, significantly increased bacterial virulence to 30% of the level of the wild type, whereas the introduction of pTrcB1sE
A and pTrcTraLE
A did not cause significant effects. The results of the tumor formation assays are similar to those of the pilus formation assay, but the strong effect of pTrcTraL and the partial restoration of tumor formation by an active-site variant of VirB1 constitute a marked difference. However, the relatively low complementation by pTrcB1, which could be caused by inefficient promoter induction by IPTG in the wound, complicates the interpretation. We therefore next chose IncQ plasmid transfer as a more quantitative assay of substrate translocation.
![]() View larger version (24K): [in a new window] |
FIG. 4. Complementation of PC1001 ( virB1) tumor formation on N. tabacum leaf disks. Strains A348 and PC1001 ( virB1) carrying pTrc200 and virB1 ortholog-carrying constructs were cocultivated with N. tabacum leaf disks for 2 days followed by elimination of the bacteria and quantitation of tumor formation at the wound sites. The strains used are as follows: A348 and PC1001 carrying pTrc200 (pTrc), pTrcB1 (VirB1), pTrcB1s (VirB1s), pTraL (TraL), pTrcB1E A (VirB1E A), pTrcB1sE A (VirB1sE A), pTrcTraLE A (TraLE A), or pTrc169 (F169). Error bars indicate standard errors (n = 14).
|
A increased pLS1 transfer, and the stimulation was modest but significant (20% of the wild-type level, comparable to TraL). Those results are qualitatively similar to those obtained in tumor formation assays.
![]() View larger version (21K): [in a new window] |
FIG. 5. Complementation of pLS1 donor activity of strain PC1001. Donor strains A348(pLS1) and PC1001 ( virB1)(pLS1) carrying pTrc200 and virB1 ortholog-carrying constructs were cocultivated with recipient strain A. tumefaciens UIA143(pTiA6) for 3 days in the presence of IPTG under virulence gene-inducing (+AS) or noninducing (-AS) conditions followed by the quantitation of pLS1-carrying recipients (TK/D = transconjugants per donor). The strains used are as follows: A348(pLS1) and PC1001(pLS1) carrying pTrc200 (pTrc), pTrcB1 (VirB1), pTrcB1s (VirB1s), pTraL (TraL), pTrcB1E A (VirB1E A), pTrcB1sE A (VirB1sE A), pTrcTraLE A (TraLE A), pTrc169 (F169), or pTrc523 (HP0523). Error bars indicate standard deviations derived from the results from three independent experiments.
|
![]() View larger version (22K): [in a new window] |
FIG. 6. Complementation of pLS1 recipient activity of strain PC1001 ( virB1). Donor strain A348(pLS1) was cocultivated with recipient strains A348(pTrc200) and PC1001 carrying pTrc200 and/or virB1 ortholog-carrying constructs for 3 days in the presence of IPTG under virulence gene-inducing conditions followed by the quantitation of pLS1-carrying recipients (TK/R = transconjugants per recipient). The strains used are as follows: A348(pTrc200) and PC1001( virB1) carrying pTrc200 (pTrc), pTrcB1 (VirB1), pTrcB1s (VirB1s), pTraL (TraL), pTrcB1E A (VirB1E A), pTrcB1sE A (VirB1sE A), pTrcTraLE A (TraLE A), or pTrc169 (F169). Error bars indicate standard deviations derived from the results from three independent conjugations.
|
|
|
|---|
This led to the hypothesis that in contrast to other T4SS components (10, 25, 46), exchange between different VirB1 orthologs may be possible (28). We directly tested this hypothesis here and found that VirB1s from B. suis and TraL from pKM101 partly complemented the virB1 defect of A. tumefaciens strain PC1001. A variety of different assay systems were employed to substantiate this finding, such as T-pilus formation, tumor formation, and IncQ plasmid donor and IncQ plasmid recipient activity, and the results of all assays were qualitatively similar. In spite of the limited degree of sequence similarity, VirB1s complemented the virB1 defect to a similar level as VirB1 from A. tumefaciens. In contrast, the complementation by TraL, which has approximately the same sequence similarity to VirB1 as VirB1s, was reduced but still significant. In addition to the previously assigned VirB1 orthologs, we identified the H. pylori HP0523 gene product as a putative transglycosylase. HP0523 and the F plasmid-encoded ORF169 gene product are significantly smaller than VirB1, VirB1s, and TraL, and the overall sequence identities to VirB1 are below 20%. These proteins essentially comprise the N-terminal domain of VirB1, which partly complements virB1 defects (37). The putative active-site residues are well conserved, suggesting a function of these proteins as lytic transglycosylases. The facts that the HP0523 gene product is essential for the virulence of H. pylori (21, 42) and that P19 of plasmid R1, which is almost identical to ORF169, is required for efficient conjugative transfer (5), support a role for these proteins in T4SS assembly. While we did not observe complementation of the A. tumefaciens virB1 defect, which may be due to low protein levels in the cell, the results of an independent study support a role for HP0523 in T4SS assembly in the cell envelope (42).
An obvious difference between the virB1 complementing and noncomplementing orthologs is the length of the proteins. VirB1, VirB1s, and TraL share a C-terminal extension, which is processed and secreted in the case of VirB1. Production of the C-terminal processing product VirB1* alone partly complemented virB1 defects of A. tumefaciens, implying that this part of the protein may exert an effect during the type IV secretion process independent of the N-terminal domain (37). VirB1* was cross-linked to VirB9 in vivo (2), and mutational alterations of different residues N- and C-terminal to the processing site negatively affected processing and complementation (C. Höppner and C. Baron, unpublished data). Thus, the interactions of the C-terminal processing product with other components of the T4SS machinery may determine the outcome of complementation experiments, and this may explain our inability to achieve complementation with the ORF169 and HP0523 gene products. One possibility to test this hypothesis would be to study the complementation by fusion proteins of ORF169 and HP0523 with the VirB1* domain.
Based on results obtained with the yeast two-hybrid system, it was recently suggested that VirB1 may interact with several VirB proteins, such as VirB4, VirB8, VirB9, VirB10, and VirB11 (53). Supporting this hypothesis are recent data demonstrating that VirB1, VirB2, and VirB3 impact the subcellular localization of VirB10 (35). To distinguish between the contribution of the transglycosylase and other activities of the proteins, we investigated the complementation by active-site mutants of VirB1, VirB1s, and TraL. Exchange of the active-site Glu residue by Ala did not affect the processing of VirB1 and the secretion of VirB1*, showing that these processes do not require the transglycosylase active site. In a previous study, a similar alteration of the active site of VirB1 abolished its ability to complement tumor formation on Kalanchoë diagremontiana leaves (39). In contrast to that, we found that the alteration of the active-site Glu residue by Ala reduced the activity of the modified gene product but did not lead to a loss of complementation. The difference to previous results may be explained by the higher expression from the trc promoter used in this work and by the choice of assay system. Mushegian et al. did not monitor the level of VirB1 and used the K. diagremontiana leaf puncture assay (39), which is inherently difficult to quantify, whereas we chose a variety of different assay systems. In contrast to the results obtained with VirB1E
A, VirB1sE
A and TraLE
A did not complement the virB1 defect in PC1001. Thus, the orthologs can exclusively substitute for the activity of VirB1 from the putative transglycosylase active site. The complementation by the wild-type genes may be efficient due to the strong expression from the trc promoter, but since specific antisera were not available, we could not directly monitor protein levels. In contrast, VirB1 may interact with other VirB proteins (35, 53), and due to the limited sequence similarity, VirB1s and TraL may not be able to fulfill these transglycosylase-independent function(s). The substantial residual activity of VirB1E
A is in accord with the hypothesis that VirB1 may have additional functions, and previous work from other groups lends further support to this notion (37, 53). Further studies are required to dissect the different contributions of VirB1 transglycosylase activity and VirB protein interactions to T4SS function(s).
This work was supported by grants from the DAAD/Procope, the Deutsche Forschungsgemeinschaft DFG (Ba 1416-2/2), and the European Union Frame Programme 5 (contract QLK2-CT-2001-01200) to C.B. and by an NSF grant (MCB9817149) to A.N.B.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»